Literature DB >> 2838713

Agonist and antagonist binding to tachykinin peptide NK-2 receptors.

S H Buck1, S A Shatzer.   

Abstract

The binding of tachykinin peptides and fragments to NK-2 receptor sites in hamster urinary bladder membranes was examined and compared to binding to NK-1 receptor sites in rat submandibular gland. Neurokinin A (NKA) and its C-terminal fragments bound with highest NK-2 affinity and selectivity. N-terminal fragments of NKA did not bind to either type of receptor. Kassinin and eledoisin were NK-2 selective while physalaemin, phyllomedusin, and uperolein were NK-1 selective. Of fifteen tachykinin antagonists examined, none exhibited appreciable affinity or selectivity (relative to agonists) for NK-1, NK-2, or rat cerebral cortical NK-3 receptor sites. NKA binding to NK-2 sites was stimulated by Mn++ greater than Mg++ greater than Ca++. At the optimal concentration, the Mn++ stimulation was due to both an increased Bmax and increased affinity. The nonhydrolyzable guanine nucleotide, GppNHp, reduced agonist binding but not antagonist binding to NK-2 receptor sites. The nucleotide effect was due to a reduction in both Bmax and affinity and was potentiated by Mn++. The results indicate that tachykinin NK-2 receptor sites possess distinct structural requirements for agonists and are linked to a G-protein coupling system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838713     DOI: 10.1016/0024-3205(88)90246-9

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  16 in total

1.  Solution structure of the tachykinin peptide eledoisin.

Authors:  R Christy Rani Grace; Indu R Chandrashekar; Sudha M Cowsik
Journal:  Biophys J       Date:  2003-01       Impact factor: 4.033

2.  Influence of perivascular peptides on endoneurial blood flow and microvascular resistance in the sciatic nerve of the rat.

Authors:  D W Zochodne; L T Ho
Journal:  J Physiol       Date:  1991-12       Impact factor: 5.182

3.  Pharmacological properties of a C-fibre response evoked by saphenous nerve stimulation in an isolated spinal cord-nerve preparation of the newborn rat.

Authors:  J C Nussbaumer; M Yanagisawa; M Otsuka
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

4.  Membrane-Induced Structure of Scyliorhinin I: A Dual NK1/NK2 Agonist.

Authors:  Anjali Dike; Sudha M Cowsik
Journal:  Biophys J       Date:  2005-02-24       Impact factor: 4.033

5.  Pharmacological profile of a tachykinin antagonist, spantide, as examined on rat spinal motoneurones.

Authors:  M Yanagisawa; M Otsuka
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

6.  Inhibition of nitric oxide synthesis reveals non-cholinergic excitatory neurotransmission in the canine proximal colon.

Authors:  C W Shuttleworth; K M Sanders; K D Keef
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

7.  Evidence that tachykinin NK1 and NK2 receptors mediate non-adrenergic non-cholinergic excitation and contraction in the circular muscle of guinea-pig duodenum.

Authors:  V Zagorodnyuk; P Santicioli; C A Maggi; A Giachetti
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

8.  Characterization of a tachykinin peptide NK2 receptor transfected into murine fibroblast B82 cells.

Authors:  P L van Giersbergen; S A Shatzer; A K Henderson; J Lai; S Nakanishi; H I Yamamura; S H Buck
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

9.  Naloxone-reversible effect of spantide on the spinally mediated behavioural response induced by neurokinin-2 and -3 receptor agonists.

Authors:  T Sakurada; Y Manome; K Katsumata; H Uchiumi; K Tan-No; S Sakurada; K Kisara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

10.  Tachykininergic transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of NK2 receptors.

Authors:  L Bartho; P Santicioli; R Patacchini; C A Maggi
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.